C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 73 700 KRW 2.08% Market Closed
Market Cap: ₩3.2T

Operating Margin

10.2%
Current
Improving
by 1.3%
vs 3-y average of 8.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
10.2%
=
Operating Income
₩52.8B
/
Revenue
₩517.6B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
10.2%
=
Operating Income
₩52.8B
/
Revenue
₩517.6B

Peer Comparison

Country Company Market Cap Operating
Margin
KR
Celltrion Pharm Inc
KOSDAQ:068760
3.2T KRW
Loading...
US
Eli Lilly and Co
NYSE:LLY
964.8B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.9B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
149.5B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.6B EUR
Loading...

Market Distribution

Higher than 81% of companies in Korea
Percentile
81th
Based on 2 615 companies
81th percentile
10.2%
Low
-163 055.6% — -2.2%
Typical Range
-2.2% — 6.8%
High
6.8% — 22 874.8%
Distribution Statistics
Korea
Min -163 055.6%
30th Percentile -2.2%
Median 2.7%
70th Percentile 6.8%
Max 22 874.8%

Celltrion Pharm Inc
Glance View

Market Cap
3.2T KRW
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

Celltrion Pharm Inc Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
10.2%
=
Operating Income
₩52.8B
/
Revenue
₩517.6B
What is Celltrion Pharm Inc's current Operating Margin?

The current Operating Margin for Celltrion Pharm Inc is 10.2%, which is above its 3-year median of 8.9%.

How has Operating Margin changed over time?

Over the last 3 years, Celltrion Pharm Inc’s Operating Margin has increased from 9.6% to 10.2%. During this period, it reached a low of 5.5% on Jun 30, 2024 and a high of 11.2% on Jun 30, 2023.

Back to Top